Navigation Links
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
Date:6/16/2009

Multi-Center, Randomized Trial to Test Unique Delivery System Using Living Cells to Enhance Wound Healing Marks Milestone for Fort Worth, Texas-based Specialty Biopharmaceutical Company

FORT WORTH, Texas, June 16 /PRNewswire/ -- HEALTHPOINT, Ltd. today announced that it has enrolled the first of a planned 235 subjects into a Phase II dose response study investigating an experimental, cell-based wound therapy ---HP802-247---intended for the treatment of venous leg ulcers. HP802-247 is a topical spray containing living keratinocytes and fibroblasts. The first patient was enrolled at The Center for Clinical Research near San Francisco, Calif., led by the site's principal investigator, Alexander Reyzelman, DPM. The study is being conducted by 28 investigators in 18 states.

"The start of enrollment into this multi-center, randomized trial is an important milestone for HEALTHPOINT," said Bert Slade, M.D., FAAAAI, Chief Medical Officer at HEALTHPOINT and co-author of the trial protocol. "This is the largest cell therapy dose ranging trial ever undertaken in the area of wound healing."

The trial is the second of two planned-dose response trials, extending the dose range being tested and exploring two plausible dose frequencies. Enrollment into the trial is preceded by screening and run-in phases and is expected to continue through the middle of 2010. The first trial showed promising results over a four-fold range of cell concentrations administered weekly.

This trial is evaluating the benefits and safety of enhancing wound healing by using metabolically active donor cells to support the patient's own skin cells' healing ability. HP802-247 utilizes allogeneic cells, which are living human cells derived from an individual donor that are subsequently grown in a tissue culture, and then applied to an unrelated patient. The HP802-247 product consists of both keratinocytes and fibrobl
'/>"/>

SOURCE HEALTHPOINT, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
2. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
3. MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series
4. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
5. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
6. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
7. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
8. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
9. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
10. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
11. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...YDNEY, Nov. 25 HeartWare... leading innovator and provider of less invasive, ...lutionizing the treatment of advanced heart failur... investor presentation at the 21st Annual Piper Ja...nesday, December 2, 2009. The conference is being ...
(Date:11/24/2009)...ewswire/ -- ,, WHAT: Rom Houbens, a Belgian m...wing an auto accident, was actually fully consciou...f a Good Morning America segment. The DynaVox Eye...people with Locked-in Syndrome and other condition...ing America -- Tuesday, November 24 available on...
(Date:11/24/2009)... Vermillion, Inc. (VRML) ...ts Plan of Reorganization and Disclosure Statement...Bankruptcy Court for the District of Delaware. A h...ement is presently scheduled for December 8, 2009,...scheduled for January 7, 2010. ,, The Plan cal...
Breaking Medicine Technology:HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Vermillion Files Plan of Reorganization 4deverus 28TM 29 Expands Operations Overseas 59602 1deverus 28TM 29 Expands Operations Overseas 59602 2Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 1Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 2Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 3Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 4Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 5Nutrition 21 Announces Financial Results for Q4 of Fiscal 2009 and Full Year Fiscal 2009 14496 6Loss of tumor suppressor and DNA maintenance proteins causes tissue demise 59595 1Loss of tumor suppressor and DNA maintenance proteins causes tissue demise 59595 2
(Date:11/26/2009)...tetrathiomolybdate (TM) has been shown in studies ..., a disease caused by an overload of copper, and c...y little, however, is known about how the drug wor...Northwestern University researchers now has provid...ture of TM bound to copper-loaded metallochaperone...
(Date:11/26/2009)...re letters from the North Pole, Textsanta.net lets...om Santa , North Pole, AK...fficiencies at the North Pole Santa Claus has adde...r the globe informed of his Christmas progress at ...h department have identified a large and growing p...
(Date:11/26/2009)...n Communications announces a highly effective and ...s struggling to make an economic recovery. , ...lu fears is the type of challenge that could send ...ing to Dr. David Benton, business growth expert an...tem – The Rfactor Intensive . “Fear...
(Date:11/25/2009)...Nov. 25 The Bartle Hall Convention...st medical clinic on Dec. 9-10, when Kansas City h...s for uninsured people. ,, "This free clinic ev...ecause it will extend over two days instead of jus...ekend," Sheri Wood, executive director of the Kans...
(Date:11/25/2009)...RNewswire/ - Sentinelle Medical Inc., a leading ma...ization software launches a suite of new leading e... imaging software platform at this year,s Radiolog...g in Chicago, Nov. 30 - Dec. 5, 2009 (Booth 5800, ... quality images generated by Sentinelle,s speciali...
Breaking Medicine News(10 mins):Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 4
...cessed Meat and Alcohol, WASHINGTON, Oct. 31 The...of developing cancer is much stronger now than,eve...day by the American,Institute for Cancer Research ...d convincing., Released today at a Washington new...
...th behavior change increasing, LYNDHURST, N.J., O... 3rd quarter of 2007, with agreements to offer new...ves at initial rollout,six million when programs a...cipation in client-sponsored population health,man...
...cancer death worldwide, the occurrence of esophage...and gender. Esophageal cancer is thought to be tri... interact with the host genome. Researchers have l...geal cancer. , One research article was published...
...) (ziconotide intrathecal infusion) as a First-L...ications, CHARLESTON, W.Va., Oct. 31 The 2007 Po...ading national pain management,physicians from the...romodulation, a neurology and pain,publication for...
...Call/ - BioMS Medical Corp (TSX:,MS), a leading de...), today,announced that Mr. Kevin Giese, President... and Renshaw 9th Annual Healthcare Conference in N...nual Healthcare Conference ----------------------...
...ians and other,healthcare providers have been cont...lthchannels forum,( http://www.healthcommunities.c...ly, the one-thousandth physician post was submitte...al, unbiased, and physician-developed and -monitor...
Other Medicine News:Health News:Landmark Report: Excess Body Fat Causes Cancer 2Health News:Landmark Report: Excess Body Fat Causes Cancer 3Health News:IncentOne Adds 14 New Clients Year to Date to Health and Productivity Division 2Health News:IncentOne Adds 14 New Clients Year to Date to Health and Productivity Division 3Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Polyanalgesic Consensus Panel's New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 2Health News:Polyanalgesic Consensus Panel's New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 3Health News:Polyanalgesic Consensus Panel's New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 4Health News:Polyanalgesic Consensus Panel's New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5Health News:BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:Free Site Offering Patient-Physician Dialog Reaches Milestone 2
Ovation BioNatural Pipette, two-stroke, fixed volume, 500L
Ovation BioNatural Pipette, one-stroke, fixed volume, 500L
Finnpipette Focus Fixed Volume, 500ul
...s a synonym for pipetting accuracy, a smooth strok...ting comfort. Its single, multifunctional button i...t as well as eject the tip. Product features:Eppen...and precision. Ejection sleeve can be removed to f...
Medicine Products: